Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy
- Conditions
- Breast Neoplasms
- Interventions
- Drug: NET or NCT
- Registration Number
- NCT05673850
- Lead Sponsor
- Peking University
- Brief Summary
In estrogen receptor (ER)-positive breast cancer (BC), human epidermal growth factor receptor-2 (HER2)-low ones are reported to have distinct clinical and molecular features from those with HER2-zero or HER2-positive status. However, the association between HER2-low status with response to endocrine therapy is largely unknown. In this study, we included 518 ER-positive BC patients who received either neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NCT). The pathologic complete response rate (pCR) of HER2-low and HER2-zero tumors re-sponding to neoadjuvant therapies were compared. The difference in disease-free survival (DFS) and overall survival (OS) between the two groups was also analyzed. The pCR (defined as ypT0/isNx) in HER2-low BCs and in HER2-zero BCs for NET cohort and NCT cohort were compared.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 518
patients diagnosed with invasive breast cancer and who received surgery from 2015 to 2021
none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description NET NET or NCT - NCT NET or NCT -
- Primary Outcome Measures
Name Time Method pathologic complete response rate (pCR) through study completion, an average of 6 months ypT0/isNx
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Peking University Cancer Hospital
🇨🇳Haidian, Beijing, China